JPRN-jRCTs031180108已完成3 期
A prospective randomized control study of combination therapy with methimazole and a cholesterol absorption inhibitor as for the initial treatment of childhood onset Graves' disease - ABCTx
AGASAKI KEISUKE0 个研究点目标入组 69 人开始时间: 2019年2月5日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 69
研究概览
简要总结
The superiority of the MMI and cholesterol absorption inhibitor combination group compared to the MMI monotherapy group was not verified in patients with newly diagnosed childhood-onset Graves' disease with moderate or severe thyrotoxicosis.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 10age old 至 <= 16age old（—）
- 性别
- All
入选标准
- •1) Patients with newly diagnosed Graves' disease
- •2) Serum FT4 value more than 5.0 ng/dl
- •3) Written informed consent from the patients' parents or legal guardians.
- •4) Age from 10 years old to under 16 years old
排除标准
- •1) Patients with thyrotoxic crisis
- •2) Patients who receive pharmacotherapy for diabetes, hepatic and renal disease
- •3) Medical history of Graves' disease. Patients who have already used cholesterol absorption inhibitor.
- •4) Use of coumarin anticoagulants, digitalis, and bile acids preparations
- •5) Patients with complete obstruction of the biliary tract
- •6) Patients with intestinal obstruction
- •7) Judged inappropriate for this study by the physicians.
研究者
相似试验
已完成
4 期
Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction after Coronary Stenting, A Randomized Controlled TrialJPRN-UMIN000005597Department of Cardiovascular Medicine Kyushu University Graduate School of Medical Sciences260
已完成
3 期
A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)Type 2 Diabetes MellitusHypercholesterolemiaNCT00110435Organon and Co1,229
已完成
3 期
Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)HypercholesterolemiaNCT00090298Organon and Co2,815
终止
不适用
Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event AssessmentsHypertensionType 2 DiabetesHypercholesterolemiaNCT01173939Positive Trial Group10,000
已完成
3 期
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)Coronary DiseaseHypercholesterolemiaNCT00092625Organon and Co442